We are happy to announce that our team has raised ~3 million EUR to advance the first-in-human study of our migraine prophylaxis asset, VRG-145. With these proceeds, we will complete CMC development and execute a Phase 1 study to assess safety & PK on 36 healthy volunteers.
Over the past year, we completed regulatory consultations both with the FDA & the NNGYK, finalized the design of the first-in-human Phase 1 study, and strengthened our IP portfolio with the publication of two of our patents by the USPTO & EPO, and the filing of an additional priority patent application with the USPTO.
The financing round is led by PMK Ventures, the investment arm of PMK-Group, with participation from Széchenyi Alapok - Széchenyi Funds& Vascular Group.
Alongside this financing, Novamigra is currently in discussions with multiple European pharmaceutical companies and aims to close the remainder of its financing round while preparing for potential strategic partnerships.
